Health Condition 1: A419- Sepsis, unspecified organism
Conditions
Interventions
Intervention1: Continuous infusion of neostigmine methyl sulphate for 5 days: In control arm (Group 1), standard therapy will be given to patients as per standard Adult Intensive Care Unit (AICU) pro
Sponsors
All India Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: Patients aged above 18 years Patients having clinical features suggestive of septic shock ( Requiring vasopressor support to maintain Mean Arterial Pressure greater than 65 mm Hg)
Exclusion criteria
Exclusion criteria: 1.Known absolute contraindications against cholinesterase inhibitor such as, myotonic dystrophy, depolarization block by depolarizing muscle relaxant, intoxication by irreversibly acting cholinesterase inhibitors, closed craniocerebral trauma. 2.Known relative contraindications against cholinesterase inhibitors eg bronchial asthma, brady cardia, A-V conduction disturbances. 3.Pregnant and lactating women. 4.Having undergone solid organ transplantation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the level of proinflammatory cytokine TNF-alpha in septic shock patients treated with standard therapy & those treated with neostigmine adjunctive therapy, before starting therapy, on day 3 of therapy & on day 5 of therapyTimepoint: Day 1 Day 3 Day 5 of neostigmine therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To compare change in SOFA score after 120hrs of neostigmine adjunctive therapy. 2. To compare APACHEII score after 120hr s of neostigmine adjunctive therapy. 3. To compare the mortality in both the groups after 28 days.Timepoint: Day 1,Day 2,Day 3,Day 4,Day 5,Day 28 | — |
Countries
India
Contacts
Public ContactDr Mirdhu Bashni T
All India Institute Of Medical Sciences Jodhpur
Outcome results
None listed